School of Biological Sciences, Faculty of Science, and the Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals NHS Foundation Trust (CMFT), Manchester M13 9WL, UK and Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, and Manchester Academic Health Science Centre, Manchester M13 9NT, UK.
Metallomics. 2017 Aug 16;9(8):1106-1119. doi: 10.1039/c7mt00074j.
Datasets comprising simultaneous measurements of many essential metals in Alzheimer's disease (AD) brain are sparse, and available studies are not entirely in agreement. To further elucidate this matter, we employed inductively-coupled-plasma mass spectrometry to measure post-mortem levels of 8 essential metals and selenium, in 7 brain regions from 9 cases with AD (neuropathological severity Braak IV-VI), and 13 controls who had normal ante-mortem mental function and no evidence of brain disease. Of the regions studied, three undergo severe neuronal damage in AD (hippocampus, entorhinal cortex and middle-temporal gyrus); three are less-severely affected (sensory cortex, motor cortex and cingulate gyrus); and one (cerebellum) is relatively spared. Metal concentrations in the controls differed among brain regions, and AD-associated perturbations in most metals occurred in only a few: regions more severely affected by neurodegeneration generally showed alterations in more metals, and cerebellum displayed a distinctive pattern. By contrast, copper levels were substantively decreased in all AD-brain regions, to 52.8-70.2% of corresponding control values, consistent with pan-cerebral copper deficiency. This copper deficiency could be pathogenic in AD, since levels are lowered to values approximating those in Menkes' disease, an X-linked recessive disorder where brain-copper deficiency is the accepted cause of severe brain damage. Our study reinforces others reporting deficient brain copper in AD, and indicates that interventions aimed at safely and effectively elevating brain copper could provide a new experimental-therapeutic approach.
阿尔茨海默病(AD)大脑中同时测量多种必需金属的数据集很少,并且可用的研究并不完全一致。为了进一步阐明这个问题,我们采用电感耦合等离子体质谱法测量了 9 例 AD(神经病理学严重程度 Braak IV-VI)和 13 例对照的 7 个脑区死后的 8 种必需金属和硒水平,这些对照生前具有正常的智力功能,并且没有脑部疾病的证据。在所研究的区域中,有三个区域在 AD 中发生严重的神经元损伤(海马体、内嗅皮层和颞中回);三个区域受到的影响较小(感觉皮层、运动皮层和扣带回);一个区域(小脑)相对未受影响。对照组中各脑区的金属浓度存在差异,大多数金属的 AD 相关变化仅发生在少数几个区域:受神经退行性变影响更严重的区域通常会改变更多的金属,而小脑则表现出独特的模式。相比之下,所有 AD 脑区的铜水平都显著降低,降至对照值的 52.8-70.2%,与全脑铜缺乏一致。这种铜缺乏可能是 AD 的致病因素,因为水平降低到接近 Menkes 病的水平,Menkes 病是一种 X 连锁隐性遗传疾病,大脑铜缺乏被认为是严重脑损伤的原因。我们的研究强化了其他报道 AD 大脑铜缺乏的研究,并表明旨在安全有效地提高大脑铜水平的干预措施可能为新的实验治疗方法提供了依据。